Gene Expression during Panobinostat Dosing
Ontology highlight
ABSTRACT: A clinical study evaluating the dosing of an oral HDACi panobinostat in patient infected with HIV-1. Dosing was 20 mg orally, 3 times weekly, every other week for a total of 8 weeks. Gene expression was evaluated in whole PBMCs at baseline (Visit 2), after 3 doses (Visit 4), 4 weeks after dosing (Visit 12) and 6 months after dosing (Visit 13) using the Affymetrix HTA 2.0 gene expression chip
ORGANISM(S): Homo sapiens
PROVIDER: GSE109792 | GEO | 2018/01/30
REPOSITORIES: GEO
ACCESS DATA